Pivot Pharma Launches Cannabis and Nutraceutical Facility in Quebec

Market Exclusive | November 26, 2019

Pivot Pharmaceuticals has launched its cannabis and nutraceutical manufacturing facility in Dollard-des-Ormeaux, Quebec, Canada. The facility, along with R&D and pilot-scale laboratories, is comprised of 43 000 square feet of production and packaging space designed to optimize the manufacturing processes of Pivot branded value-added CBD and nutraceutical consumer products. The company plans to start the production activities in the next three months, pending the Health Canada license reception. Pivot is nearing the completion of its state-of-the-art building and is preparing the submission of its site evidence package to Health Canada, the final step toward securing the Health Canada license. The infrastructure will be used to develop novel formulations and production of Pivot’s CBD, phytocannabinoid and micronutrient product lines using Pivot’s patented and drug delivery technologies. “This facility will enable us to launch our product pipeline in the Canadian market and thus further consolidating Pivot’s strategic positioning with ramping sales of specialty CBD products and micronutrient formulations in Germany and planed product launches in the U.S. marketplace in Q1 2020,” Pivot CEO Dr. Toni Rinow stated.

Spotlight

We are working with governments, schools, scientific institutions, and our own partners, to inspire young people with exciting opportunities that studying STEM subjects (science, technology, engineering, and mathematics) can bring.

Spotlight

We are working with governments, schools, scientific institutions, and our own partners, to inspire young people with exciting opportunities that studying STEM subjects (science, technology, engineering, and mathematics) can bring.

Related News

BUSINESS INSIGHTS

Seagen and Sanofi Announced Partnership for the Development and Commercialization of Multiple Novel Antibody-Drug Conjugates

Seagen Inc. | March 17, 2022

Sanofi and Seagen signed an exclusive partnership agreement to discover, develop, and market antibody-drug conjugates targeting three cancer targets. Sanofi's patented monoclonal antibody technology and Seagen's proprietary ADC technology will be used. Sanofi presently has one ADC under development, an antibody designed to deliver strong anti-cancer medications to tumor cells expressing a particular protein. “We are excited to be working with Sanofi, a global biopharmaceutical leader, to identify new ways to address unmet medical needs of cancer patients potentially. Jointly developing novel ADCs by combining antibodies from Sanofi with Seagen’s proprietary ADC technology aligns with our strategic priorities to expand the global potential of our pipeline with new first- or best-in-class programs.” Clay Siegall, Ph.D., President, and Chief Executive Officer, Seagen According to John Reed, M.D., Ph.D., Global Head of Research and Development, Sanofi, “This collaboration will enable the synergistic combination of molecules and platforms to produce candidate medicines to bring renewed hope to cancer patients and their families. We look forward to joining forces with Seagen to collaboratively design and develop promising medicines by advancing antibody-drug conjugate science.” Seagen and Sanofi will co-fund worldwide development operations and split any future earnings equally under the terms of the agreement. In addition, once each of the three targets is chosen, Sanofi will provide an undisclosed payment to Seagen. The collaboration's first goal has already been established.

Read More

PHARMACY MARKET

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

Atara Biotherapeutics, Inc. | October 04, 2021

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will receive an upfront payment of USD 45 million, and up to approximately USD 320 million in additional regulatory and sales milestone payments, plus significant double-digit tiered royalties as a percentage of net sales. Atara will continue to be responsible for the pivotal ALLELE study in PTLD as well as submitting the EU Marketing Authorization Application (MAA) for tabelecleucel in patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), which is on track for November 2021. Atara will also remain responsible for the Phase 2 multi-cohort study, which is evaluating tab-cel® in six additional patient populations with the goal of label expansion in EBV-driven cancers. Pierre Fabre will lead all commercialization and distribution activities in the territories, as well as medical and regulatory activities after the anticipated MAA approval in Europe. As part of the transaction, Atara will also provide manufacturing services for tab-cel® to be paid by Pierre Fabre. Atara is a leader in T-cell immunotherapy, leveraging its first-in-kind allogeneic off-the-shelf EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases. Tab-cel® is the Company’s lead candidate in development for EBV-positive cancers, including EBV+ PTLD, where it is currently being investigated in adults and children in the Phase 3 ALLELE study. Tab-cel® has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation by the European Medicines Agency (EMA). Pierre Fabre is a science-driven company that brings significant commercialization expertise through its integrated Oncology Business Unit, its deep knowledge of Bone Marrow Transplant centers and a track record of successful launches through partnerships, Our Companies’ complementary capabilities will expand access to tab-cel®, a potentially transformative investigational allogeneic off-the-shelf T-cell immunotherapy, to patients worldwide who suffer from EBV+ PTLD and other EBV-driven cancers. - Pascal Touchon, President and CEO of Atara. Pierre Fabre enjoys a 35-year long experience in oncology covering innovation, development, manufacturing and commercialization. Its Medical Care division has declared oncology as its main R&D and commercial priority, focusing on targeted therapies, biotherapies, and immuno-oncology. Its therapeutic areas include high unmet medical needs and cover colorectal, breast, lung cancers, melanoma, and pre-cancerous conditions like actinic keratosis. The company has also developed a strong know-how in leveraging global partnerships with biotechnology and pharmaceutical companies, as demonstrated by several successful collaborations in oncology. PJT Partners served as the exclusive financial advisor to Atara. About Tabelecleucel Tabelecleucel (tab-cel®) is an off-the-shelf, allogeneic T-cell immunotherapy in development for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). EBV+ PTLD is a type of lymphoma (cancer) that may occur after a solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). There are currently no approved treatments indicated to treat PTLD and if left untreated, PTLD can have life-threatening consequences. Tab-cel® is currently being investigated in the Phase 3 ALLELE study to assess efficacy and safety for the treatment of EBV+ PTLD in SOT and HCT after failure of standard of care. Tab-cel® has been granted Breakthrough Therapy Designation for EBV+ PTLD following allogeneic HCT by the U.S. Food and Drug Administration (FDA) and PRIME designation by the European Medicines Agency (EMA) for the same indication. Tab-cel® has orphan drug designation in the U.S. and EU. About Pierre Fabre Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio ranges across several medical franchises and international brands, including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive and Pierre Fabre Oral Care. In 2020, Pierre Fabre generated €2.3 billion in revenues, 65% of which came from international sales. Established in the South-West area of France since its creation, and manufacturing over 95% of its products in France, the Group employs some 10,000 people worldwide. Its products are distributed in about 130 countries. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan. In 2020, Ecocert Environment assessed the Group’s corporate social and environmental responsibility approach in accordance with the ISO 26000 sustainable development standard for the 2nd consecutive year and confirmed its “Excellence” level. For further information, please visit the Pierre Fabre website at www.pierre-fabre.com. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Read More

BUSINESS INSIGHTS

Biosero Collaborates with Araceli Biosciences for High-Content Analysis

Biosero, Inc. | February 02, 2022

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform into automated workflows controlled by Biosero’s Green Button Go® software suite. The Endeavor platform offers extremely rapid imaging for high-content analysis projects. In just minutes, the instrument can provide subcellular resolution of every cell in plates with 96 wells, 384 wells, or 1,536 wells. Through this collaboration, scientists can now incorporate the Endeavor system into automated lab pipelines that are dynamically scheduled and orchestrated via Green Button Go software. “Endeavor is the first high-content system to offer simultaneous whole-well, high-resolution scanning at an order of magnitude higher throughput than current platforms. We are excited to team up with Biosero so we can unlock the full potential of the Endeavor platform for highly automated lab environments,” Jeffrey Harris, General Manager of Araceli Biosciences Biosero’s Green Button Go software allows scientists to automate workflows ranging from a single workstation to operations that span multiple labs. With a number of extensions, hundreds of available drivers, and an intuitive control interface with drag-and-drop capabilities, Green Button Go software is flexible, scalable, and easily customizable for a broad array of laboratory needs. “Biosero’s commitment to a hardware-agnostic approach means that we can work with leading technology developers to ensure that our customers get to choose the best tools for their needs,” said Tom Gilman, CEO of Biosero. “We are pleased to collaborate with Araceli for its game-changing technology to enable the next generation of automated high-content image analysis.” Biosero will be offering demonstrations of its Green Button Go software at the upcoming SLAS2022 International Conference and Exhibition taking place February 5-9 in Boston. Please visit us at booth 1413 to learn more. About Araceli Biosciences Araceli Biosciences is a data-driven technology company focused on disrupting the status quo of drug discovery by fusing innovative hardware platforms with proprietary AI-powered software. Araceli’s high content analysis platform Endeavor™ combines unmatched speed and resolution to address longstanding bottlenecks in pharmaceutical research and development. Providing ten times the throughput and double the resolution of previous platforms, Endeavor is revolutionizing drug discovery by delivering accelerated target identification and selection. With a strong industrial pedigree, Araceli is poised to usher in a new era of drug discovery. About Biosero, Inc. Biosero, now a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Our Green Button Go Scheduler software and integration services match laboratory automation to your science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Our Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. We are passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs.

Read More